



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

27th October, 2016

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release –Q2- FY16-17

Please find enclosed a press release issued by the Company in respect of financial results for the second quarter ended September 30, 2016.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
General Manager – Administration
& Company Secretary



PRESS RELEASE

Thursday, 27th October 2016, Mumbai

GlaxoSmithKline Pharmaceuticals Limited announces a 12% Sales growth for the quarter ended 30 September, 2016

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th September 2016. Sales for the quarter ended 30th September 2016 came in at Rs.783 crores, recording a growth of 12% as compared to the same prior year period. Profit from Operations at Rs. 134 crores increased by 9% against the same prior year period and diluted by mandatory price cuts.

Profit Before Tax (PBT) at Rs.152 crores and Profit After Tax (PAT) at Rs 99 crores grew by 4% and 3%, respectively, against the same prior year period, predominantly impacted by mandatory price cuts as well as a decline in Other Income.

Commenting on the results, A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said,

"The strong performance of pharmaceuticals in Q2 highlights the momentum of the company with a volume growth of 16%. This translates to a diluted value growth of 13% caused by the recent mandated price revisions. Our key brands continue to underpin the growth performance of the Company.

During the quarter, the Company successfully launched Priorix-Tetra®, a combined measles, mumps, rubella and varicella vaccine.

Our ongoing capital investment programme at our state-of-the art manufacturing site at Vemgal, Bengaluru remains on track as part of meeting the future market demand. The capital investments as well as a reduction in interest rates drive a reduction in Investment Income contributing to a PAT growth of 3% as compared to the same prior year quarter."

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts:
Ransom D'Souza
Head - Corporate Communications
Email: ransom.a.dsouza@gsk.com
Tel: +91 22 24959203

© PRIORIX-TETRA is a registered trademark